Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer

Area of Science:

• Molecular Endocrinology
• Cancer Biology
• Nuclear Receptor Signaling

Background:

• Nuclear hormone receptors regulate gene expression, impacting various tissues and cancer cells.
• Key receptors include the androgen receptor (AR), thyroid hormone receptors (TRs), retinoic acid receptors (RARs), and the vitamin D receptor (VDR).
• These receptors, often heterodimerized with retinoid X receptors (RXRs), play critical roles in prostate cancer (PCa) cell proliferation, growth, and apoptosis.

Purpose of the Study:

• To explore the roles of nuclear hormone receptors in prostate cancer (PCa).
• To investigate the potential for combinatorial treatments targeting these receptors.
• To highlight the importance of understanding receptor interactions and crosstalk for novel therapeutic strategies.

Main Methods:

• Review of existing literature on nuclear hormone receptor function in PCa.
• Analysis of the effects of specific hormonal ligands (androgens, T3, retinoic acid, vitamin D) on PCa cells.
• Examination of evidence for receptor crosstalk and interactions.

Main Results:

• Androgens promote PCa proliferation; androgen deprivation is a standard therapy.
• RARγ and TRβ activation support PCa growth.
• VDR stimulation induces PCa growth arrest, differentiation, and apoptosis.
• Accumulating evidence suggests interactions and crosstalk between these nuclear receptors.

Conclusions:

• Nuclear hormone receptors are crucial regulators in PCa.
• Individual targeting of these receptors has been explored for cancer therapy.
• Understanding receptor crosstalk is essential for developing novel combinatorial treatments for PCa and potentially other cancers.